The Impact of GLP-1 Drugs on Pregnancy
Familiarity with the trend of "Ozempic babies" exists, where females previously facing infertility challenges conceive while using GLP-1 agonists. Yet, recent investigations reveal that ceasing these medications might adversely affect gestation.
Research from Mass General Brigham indicates that individuals who discontinued popular GLP-1 treatments before or soon after conception experienced notably more weight accumulation throughout pregnancy compared to those who never used them.
Furthermore, they encountered elevated chances of severe gestational issues that endanger both the mother and infant, encompassing one of the primary factors in maternal fatalities in the United States.
These discoveries emerge as the medications' usage climbs sharply. Approximately 12% of Americans have utilized GLP-1s solely for shedding pounds, with numerous others depending on them for ailments like type 2 diabetes.
Within the human system, these substances emulate hormones produced by the intestines following meals, aiding in blood glucose control, decelerating food processing, and prolonging satiety.
However, the effects on embryos from mothers ingesting these drugs—or even on women who cease them before conception—remain mostly unexplored.
"The application of glucagon-like peptide-1 receptor agonists—or GLP-1RAs—has surged considerably, yet guidelines advise halting them prior to pregnancy due to insufficient data on their safety for developing fetuses," stated Dr. Jacqueline Maya, a child endocrinologist and principal investigator of the research, in a public statement.
"We aimed to evaluate how such cessation influences weight increase and gestation results."
To ascertain this, Maya and colleagues reviewed digital medical files from 1,792 deliveries at the Mass General Brigham health network from 2016 to 2025.
The participants, averaging 34 years old and categorized as obese by BMI standards, had all consumed GLP-1 medications within three years before conception or up to 90 days post-conception.
For outcome comparison, each expectant mother was paired with three cases from women who had never used the substances.
Findings showed that females who ceased the treatments before or early in gestation added an average of 7.2 more pounds than non-users.
Additionally, they were 32% more prone to excessive weight gain, exceeding prescribed limits during pregnancy.
This aligns with prior studies demonstrating rapid weight recovery in patients after ending GLP-1s, as the appetite-suppressing and satiation-enhancing properties diminish.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
However, dangers extended beyond the weighing scale.
The investigation also revealed a 30% greater likelihood of gestational diabetes among women with prior GLP-1 exposure, characterized by elevated blood sugar levels during gestation.
Risks Associated with Gestational Diabetes
Gestational diabetes impacts roughly 9% of U.S. pregnancies annually and typically subsides post-delivery. It is generally controllable through dietary adjustments, physical activity, glucose checks, and occasionally pharmaceuticals.
If unmanaged, it can trigger significant concerns. Infants may encounter increased odds of hypoglycemia at birth, future obesity, and other ailments, while mothers face higher risks of issues like type 2 diabetes and cardiovascular problems.
The study further indicated that women who had used GLP-1s before conception or in early gestation had a 34% elevated chance of premature birth, with infants arriving before 37 weeks.
They were also 29% more susceptible to hypertensive disorders in pregnancy (HDPs), involving elevated blood pressure existing prior or emerging during gestation.
Uncontrolled HDPs correlate strongly with grave maternal complications, such as myocardial infarction and cerebrovascular events, and rank as a top contributor to pregnancy-linked deaths in the U.S., per CDC data.
When untreated, these conditions can impede placental blood supply, hindering nutrient delivery to the fetus. This may result in problems like restricted fetal development, early delivery, and potentially fetal demise.
Positive Findings and Future Research Needs
Nonetheless, some encouraging data emerged: Investigators detected no heightened likelihood of Cesarean sections or infants with extraordinarily high or low birth weights or atypical lengths.
Still, the researchers stress that the results underscore a significant care void for females dependent on GLP-1 drugs pre-conception.
"Further investigations are essential to weigh the advantages of GLP-1s before pregnancy against the hazards of suspending them during gestation," noted Dr. Camille E. Powe, co-director of the Diabetes in Pregnancy Program at Massachusetts General Hospital and senior researcher.
"We require additional exploration to develop methods for controlling weight accumulation and mitigating risks during pregnancy after halting GLP-1 medications."
Health tracking apps like Shotlee can help monitor weight changes and other vital signs during this critical period.
